Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents

Affiliations

¹ Drug Development Unit, Christie NHS Trust, Manchester, UK. Electronic address: Alastair.Greystoke@christie.nhs.uk.
² Drug Development Unit, Christie NHS Trust, Manchester, UK.

Free article

Editorial

A Greystoke et al. Ann Oncol. 2012 Aug.

Free article

. 2012 Aug;23(8):1934-1936.

doi: 10.1093/annonc/mds116. Epub 2012 Apr 17.

¹ Drug Development Unit, Christie NHS Trust, Manchester, UK. Electronic address: Alastair.Greystoke@christie.nhs.uk.
² Drug Development Unit, Christie NHS Trust, Manchester, UK.

No abstract available

Comment on

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.
Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Wheler JJ, et al. Ann Oncol. 2012 Aug;23(8):1963-1967. doi: 10.1093/annonc/mds027. Epub 2012 Feb 29. Ann Oncol. 2012. PMID: 22377564 Free PMC article.
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
Molife LR, Alam S, Olmos D, Puglisi M, Shah K, Fehrmann R, Trani L, Tjokrowidjaja A, de Bono JS, Banerji U, Kaye SB. Molife LR, et al. Ann Oncol. 2012 Aug;23(8):1968-1973. doi: 10.1093/annonc/mds030. Epub 2012 Mar 9. Ann Oncol. 2012. PMID: 22408187